Literature DB >> 20445275

[Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].

Yasuo Suzuki1, Shinji Sato.   

Abstract

Glucocorticoids were widely used for the treatment of various disorders. Therefore, the management of glucocorticoid-induced osteoporosis (GIOP) is referred to doctors who take care of underlying diseases. Since glucocorticoid-induced bone loss is most rapid during the initial 3-6 months, primary prevention of bone loss is especially important.The Japanese Society of Bone and Mineral Metabolism have devised a guideline for the management of GCOP and bisphosphonates play a central role for the primary and secondary prevention of GIOP. Human PTH (1-34) , teriparatide is possible another beneficial drug in addition to bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445275     DOI: CliCa1005645653

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  4 in total

1.  Changes in the Dickkopf-1 and tartrate-resistant acid phosphatase 5b serum levels in preschool children with nephrotic syndrome.

Authors:  Jianjiang Zhang; Huiqin Zeng; Shuqin Fu; Peipei Shi; Miao Wang; L I Guo
Journal:  Biomed Rep       Date:  2016-03-16

2.  Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.

Authors:  Chieh-Hsin Lin; Chun-Yuan Lin; Hong-Song Wang; Hsien-Yuan Lane
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

Review 3.  Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation.

Authors:  Yujuan Li; Hongchang Gao; Lei Zhao; Jinrui Wang
Journal:  Clin Respir J       Date:  2022-06-10       Impact factor: 1.761

4.  D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density.

Authors:  Ting-I Chiang; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.